참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 1-Methylpiperazine | HCID 53167 | — |
| 반응물 | Levofloxacin q-acid | HCID 688333 | — |
| 용매 | Dimethyl Sulfoxide | HCID 679 | — |
| 생성물 | Levofloxacin | HCID 149096 | 51.9% |
반응 단계
(S)-(−)-9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid (21 mg) and N-methylpiperazine (30 mg) were dissolved in anhydrous dimethyl sulfoxide (3 ml) and stirred at 130 to 140° C. for 1 hour. After evaporating the solvent, ethanol (2 ml) was added to the residue. The solid thus precipitated was collected by filtration and washed successively with a small amount of ethanol and ether. 14 mg of the obtained powder was subjected to silica gel column chromatography with the use of 5 g of silica gel and eluted with a lower layer solution of chloroform-methanol-water (7:3:1) to thereby give (S)-(−)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid. The above-described filtration mother liquor was fractioned and subjected to thin layer chromatography (silica gel, 20×20 cm, 0.5 mm), thereby purifying by developing with a lower layer solution of chloroform-methanol-water (15:3:1). The products were combined to thereby give 14 mg of crystals of the target compound. Melting point: 220 to 228° C. (decomposition).
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US06872823B1 |
|---|
| 출처 데이터셋 | uspto-grants-2005_03 |
|---|
| ORD ID | ord-d83f128749b84a0988bb7ef17e668164 |
|---|
| 출처 메모 | uspto-grants-2005_03 |
|---|